



28 October 2022

ANNUAL GENERAL MEETING

NOTICE AND PROXY FORM

Dear Shareholder,

The Annual General Meeting (**Meeting**) of shareholders of Bioxyne Limited (ACN 084 464 193) (**Company**) will be held as on Monday, 28 November 2022 at 2pm (AEDT) at Addisons Level 12 60 Carrington Street Sydney NSW 2000.

In accordance with the *Treasury Laws Amendment (2021 Measures No. 1) Act 2021*, the Company will not be sending hard copies of the Notice of Meeting (**Notice**) to shareholders unless a shareholder has requested a hard copy. The Notice can be viewed and downloaded from the Company's website at www.bioxyne.com

The Company strongly encourages shareholders to lodge a directed proxy form prior to the meeting. Shareholders can lodge their vote by going to <https://investor.automic.com.au/#/loginsah>. Shareholders are encouraged to provide an email address in order to receive electronic communication from the Company in the future.

Your proxy form must be received by 2.00 pm (AEDT) on Saturday, 26 November 2022, being not less than 48 hours before the commencement of the Meeting. Any proxy forms received after that time will not be valid for the Meeting.

Shareholders may submit questions in advance of the Meeting by email to the Company Secretary at info@bioxyne.com using the email subject "AGM Question" by 9.00am (Sydney Time) on Friday, 25 November 2022. Shareholders who attend the Meeting will also have the opportunity to submit questions during the Meeting.

The Notice is important and should be read in its entirety. If you are in doubt as to the course of action you should follow, you should consult your financial adviser, lawyer, accountant or other professional adviser.

If you have any difficulties obtaining a copy of the Notice, please contact the Company's share registry, Automic Group, on 1300 288 664 (within Australia) or +61 2 9698 5414 (overseas).

Yours sincerely

A handwritten signature in black ink, appearing to read "Guy Robertson".

Guy Robertson
Company Secretary

This announcement has been approved for release by the Board.